The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

被引：50

作者：

Desar, Ingrid M. E. ^{[1
]}

Mulder, Sasja F. ^{[1
]}

Stillebroer, Alexander B. ^{[2
]}

van Spronsen, Dick-Johan ^{[3
]}

van der Graaf, Winette T. A. ^{[1
]}

Mulders, Peter F. A. ^{[2
]}

van Herpen, Carla M. L. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands

[3] Canisius Wilhelmina Hosp, Dept Internal Med, Nijmegen, Netherlands

来源：

ACTA ONCOLOGICA | 2009年 / 48卷 / 06期

关键词：

SU11248; TUMORS;

D O I：

10.1080/02841860902974167

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：927 / 931

页数：7

共 12 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] Time course of imaging changes of GBM during extended bevacizumab treatment [J].

Ananthnarayan, Suchitra ;

Bahng, Jennie ;

Roring, James ;

Nghiemphu, Phioanh ;

Lai, Albert ;

Cloughesy, Timothy ;

Pope, Whitney B. .

JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (03) :339-347

[3] Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors [J].

Drevs, Joachim ;

Siegert, Patrizia ;

Medinger, Michael ;

Mross, Klaus ;

Strecker, Ralph ;

Zirrgiebel, Ute ;

Harder, Jan ;

Blum, Hubert ;

Robertson, Jane ;

Juergensmeier, Juliane M. ;

Puchalski, Thomas A. ;

Young, Helen ;

Saunders, Owain ;

Unger, Clemens .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3045-3054

[4] Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy [J].

Ebos, John M. L. ;

Lee, Christina R. ;

Christensen, James G. ;

Mutsaers, Anthony J. ;

Kerbel, Robert S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (43) :17069-17074

[5] A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease [J].

Fiedler, W ;

Serve, H ;

Döhner, H ;

Schwittay, M ;

Ottmann, OG ;

O'Farrell, AM ;

Bello, CL ;

Allred, R ;

Manning, WC ;

Cherrington, JM ;

Louie, SG ;

Hong, W ;

Brega, NM ;

Massimini, G ;

Scigalla, P ;

Berdel, WE ;

Hossfeld, DK .

BLOOD, 2005, 105 (03) :986-993

[6]

Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556

[7]

Kadambi A, 2001, CANCER RES, V61, P2404

[8]

Lee CG, 2000, CANCER RES, V60, P5565

[9] Rapid vascular regrowth in tumors after reversal of VEGF inhibition [J].

Mancuso, Michael R. ;

Davis, Rachel ;

Norberg, Scott M. ;

O'Brien, Shaun ;

Sennino, Barbara ;

Nakahara, Tsutomu ;

Yao, Virginia J. ;

Inai, Tetsuichiro ;

Brooks, Peter ;

Freimark, Bruce ;

Shalinsky, David R. ;

Hu-Lowe, Dana D. ;

McDonald, Donald M. .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2610-2621

[10]

Tsuzuki Y, 2000, CANCER RES, V60, P6248

← 1 2 →